Admetsys, a startup developing artificial pancreas tech for hospitals and surgical care, won an investment from T1D Exchange. The terms of the financing were not disclosed.
A collaboration between the 2 groups is part of T1D Exchange’s initiative to support the development of automated insulin delivery technology, according to the organization.
Hospitalizations can be challenging for patients with diabetes, since they often have to turn over their insulin pumps and continuous glucose monitors. Diabetic patients are also asked to rely on clinical teams in hospitals to monitor and treat their diabetes with insulin shots and blood glucose meters, a technique that doesn’t necessarily bring about optimal glycemic control.
Admetsys has developed an Automated Insulin Delivery system to more effectively control blood glucose levels and alleviate the stresses that come along with diabetic care in an hospital environment.
The company’s device uses a standard IV line which measure glucose electrochemically every few minutes, drawing a small blood sample and returning it to the patient. The system can devise a real-time computational model of the patient’s metabolism and deliver insulin through syringe pumps to balance a patient’s glucose levels.
Admetsys has conducted 3 clinical trials and found that its artificial pancreas takes 2.5 hours, on average, to bring a patient’s blood glucose levels to a normal range. In all of the company’s clinical trials, it has not reported a single incident of hypoglycemia.
“We are both humbled and extremely grateful for the generous investment from T1D Exchange,” Admetsys CEO Jeff Valk said in prepared remarks. “For people with diabetes, glucose control is never more crucial than while admitted to a hospital or surgical center. It is our goal to deal with the surrounding issues and create an effective and safe environment for both the patient and physician. We are excited for the continued research we will be able to conduct and our company’s promise to positively impact patients’ lives.”
“The T1D Exchange mission is to accelerate treatments and improve care for people with type 1 diabetes, and our collaboration with Admetsys is the latest proof point of that dedication,” executive director & co-founder of T1D Exchange, Dana Ball, added. “Like so many other companies we partner with, Admetsys has developed a truly transformative technology that will improve our patient’s experience and health outcomes.”
